Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status

Approximately 30% of the patients with primary breast cancer who have no axillary lymph node involvement (i.e., lymph node negative) at the time of surgery will relapse within 10 years; 10%-20% of the patients with distant metastases will be lymph node negative at surgery. Axillary lymph node dissec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Diel, Ingo J. (VerfasserIn) , Kaufmann, Manfred (VerfasserIn) , Costa, Serban-Dan (VerfasserIn) , Holle, Rolf (VerfasserIn) , Minckwitz, Gunter von (VerfasserIn) , Solomayer, Erich-Franz (VerfasserIn) , Kaul, Sepp (VerfasserIn) , Bastert, Gunther (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 20 November 1996
In: Journal of the National Cancer Institute
Year: 1996, Jahrgang: 88, Heft: 22, Pages: 1652-1658
ISSN:1460-2105
DOI:10.1093/jnci/88.22.1652
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/jnci/88.22.1652
Volltext
Verfasserangaben:Ingo J. Diel, Manfred Kaufmann, Serban D. Costa, Rolf Holle, Gunter von Minckwitz, Erich F. Solomayer, Sepp Kaul, Gunther Bastert

MARC

LEADER 00000caa a2200000 c 4500
001 1882084659
003 DE-627
005 20240311150915.0
007 cr uuu---uuuuu
008 240228s1996 xx |||||o 00| ||eng c
024 7 |a 10.1093/jnci/88.22.1652  |2 doi 
035 |a (DE-627)1882084659 
035 |a (DE-599)KXP1882084659 
035 |a (OCoLC)1425891087 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Diel, Ingo J.  |d 1950-  |e VerfasserIn  |0 (DE-588)113615329  |0 (DE-627)522671934  |0 (DE-576)289768527  |4 aut 
245 1 0 |a Micrometastatic breast cancer cells in bone marrow at primary surgery  |b prognostic value in comparison with nodal status  |c Ingo J. Diel, Manfred Kaufmann, Serban D. Costa, Rolf Holle, Gunter von Minckwitz, Erich F. Solomayer, Sepp Kaul, Gunther Bastert 
264 1 |c 20 November 1996 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 28.02.2024 
520 |a Approximately 30% of the patients with primary breast cancer who have no axillary lymph node involvement (i.e., lymph node negative) at the time of surgery will relapse within 10 years; 10%-20% of the patients with distant metastases will be lymph node negative at surgery. Axillary lymph node dissection, as a surgical procedure, is associated with frequent complications. A possible alternative to nodal dissection in terms of prognosis may be the immunocytochemical detection of tumor cells in bone marrow.In a prospective study, the value of tumor cell detection (TCD) in bone marrow was compared with axillary lymph node dissection in the prognosis of primary breast cancer after surgery. Data from 727 patients with primary, operable breast cancer were included in the analysis. All patients had surgery, including axillary lymph node dissection, from May 1985 through July 1994 at the Women's Hospital of the University of Heidelberg (Federal Republic of Germany). Bone marrow aspiration at two sites on each anterior iliac crest was performed immediately after surgery while the patients were under general anesthesia. Most patients received some type of systemic adjuvant therapy. The monoclonal antibody 2E11, directed against the polymorphic epithelial mucin TAG12, was used to detect tumor cells in bone marrow samples. The association of TCD with recognized prognostic indicators was evaluated by means of chi-squared tests. Survival without the development of distant metastases (i.e., distant disease-free survival) and overall survival were estimated by use of the Kaplan-Meier method; the logrank test was used to compare survival curves. A multivariate Cox regression analysis with stratification according to adjuvant treatment type was used to assess the independent prognostic value of TCD in bone marrow in relation to other variables. Reported P values are two-sided. Results : Tumor cells were detected in the bone marrow of 203 (55%) of 367 lymph node-positive patients and in 112 (31%) of 360 lymph node-negative patients. TCD was associated with larger tumors ( P <.001), lymph node involvement ( P = .001), and higher tumor grade (i.e., more undifferentiated) ( P = .002). After a median follow-up of 36 months, patients with tumor cells in their bone marrow experienced reduced distant disease-free survival and overall survival (both P values <.001). TCD was an independent prognostic indicator for both distant disease-free survival and overall survival that was superior to axillary lymph node status, tumor stage, and tumor grade. Among patients with tumors less than 2 cm in diameter, TCD was the most powerful predictor of outcome. TCD in the bone marrow of patients with breast cancer is a valuable prognostic tool associated with negligible morbidity. Prospective randomized studies should be performed to determine whether TCD might replace axillary lymph node dissection in a defined subgroup of patients with small tumors. 
700 1 |a Kaufmann, Manfred  |d 1946-  |e VerfasserIn  |0 (DE-588)124330193  |0 (DE-627)08579046X  |0 (DE-576)294122710  |4 aut 
700 1 |a Costa, Serban-Dan  |e VerfasserIn  |0 (DE-588)1318569133  |0 (DE-627)1880215500  |4 aut 
700 1 |a Holle, Rolf  |e VerfasserIn  |0 (DE-588)105828696  |0 (DE-627)690911734  |0 (DE-576)314273638  |4 aut 
700 1 |a Minckwitz, Gunter von  |d 1964-  |e VerfasserIn  |0 (DE-588)172260035  |0 (DE-627)673296962  |0 (DE-576)133128202  |4 aut 
700 1 |a Solomayer, Erich-Franz  |d 1967-  |e VerfasserIn  |0 (DE-588)124766560  |0 (DE-627)365931101  |0 (DE-576)294490566  |4 aut 
700 1 |a Kaul, Sepp  |e VerfasserIn  |0 (DE-588)1252722125  |0 (DE-627)1794191992  |4 aut 
700 1 |a Bastert, Gunther  |d 1939-  |e VerfasserIn  |0 (DE-588)171967526  |0 (DE-627)696863006  |0 (DE-576)164650563  |4 aut 
773 0 8 |i Enthalten in  |a National Cancer Institute  |t Journal of the National Cancer Institute  |d Oxford : Oxford Univ. Press, 1941  |g 88(1996), 22, Seite 1652-1658  |w (DE-627)265780713  |w (DE-600)1465951-7  |w (DE-576)074959581  |x 1460-2105  |7 nnas 
773 1 8 |g volume:88  |g year:1996  |g number:22  |g pages:1652-1658  |g extent:7  |a Micrometastatic breast cancer cells in bone marrow at primary surgery prognostic value in comparison with nodal status 
856 4 0 |u https://doi.org/10.1093/jnci/88.22.1652  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20240228 
993 |a Article 
994 |a 1996 
998 |g 171967526  |a Bastert, Gunther  |m 171967526:Bastert, Gunther  |d 910000  |d 910400  |e 910000PB171967526  |e 910400PB171967526  |k 0/910000/  |k 1/910000/910400/  |p 8  |y j 
998 |g 1252722125  |a Kaul, Sepp  |m 1252722125:Kaul, Sepp  |d 910000  |d 910400  |e 910000PK1252722125  |e 910400PK1252722125  |k 0/910000/  |k 1/910000/910400/  |p 7 
998 |g 124766560  |a Solomayer, Erich-Franz  |m 124766560:Solomayer, Erich-Franz  |d 910000  |d 910400  |e 910000PS124766560  |e 910400PS124766560  |k 0/910000/  |k 1/910000/910400/  |p 6 
998 |g 105828696  |a Holle, Rolf  |m 105828696:Holle, Rolf  |d 910000  |d 999701  |e 910000PH105828696  |e 999701PH105828696  |k 0/910000/  |k 1/910000/999701/  |p 4 
998 |g 1318569133  |a Costa, Serban-Dan  |m 1318569133:Costa, Serban-Dan  |d 910000  |d 910400  |e 910000PC1318569133  |e 910400PC1318569133  |k 0/910000/  |k 1/910000/910400/  |p 3 
998 |g 124330193  |a Kaufmann, Manfred  |m 124330193:Kaufmann, Manfred  |d 910000  |d 910400  |e 910000PK124330193  |e 910400PK124330193  |k 0/910000/  |k 1/910000/910400/  |p 2 
998 |g 113615329  |a Diel, Ingo J.  |m 113615329:Diel, Ingo J.  |d 910000  |d 910400  |e 910000PD113615329  |e 910400PD113615329  |k 0/910000/  |k 1/910000/910400/  |p 1  |x j 
999 |a KXP-PPN1882084659  |e 4493312939 
BIB |a Y 
SER |a journal 
JSO |a {"physDesc":[{"extent":"7 S."}],"name":{"displayForm":["Ingo J. Diel, Manfred Kaufmann, Serban D. Costa, Rolf Holle, Gunter von Minckwitz, Erich F. Solomayer, Sepp Kaul, Gunther Bastert"]},"person":[{"given":"Ingo J.","family":"Diel","display":"Diel, Ingo J.","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Kaufmann, Manfred","family":"Kaufmann","given":"Manfred","role":"aut","roleDisplay":"VerfasserIn"},{"display":"Costa, Serban-Dan","given":"Serban-Dan","family":"Costa","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Holle, Rolf","given":"Rolf","family":"Holle","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Minckwitz, Gunter von","given":"Gunter von","family":"Minckwitz","role":"aut","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Erich-Franz","family":"Solomayer","display":"Solomayer, Erich-Franz"},{"role":"aut","roleDisplay":"VerfasserIn","family":"Kaul","given":"Sepp","display":"Kaul, Sepp"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Bastert, Gunther","family":"Bastert","given":"Gunther"}],"recId":"1882084659","note":["Gesehen am 28.02.2024"],"language":["eng"],"title":[{"title":"Micrometastatic breast cancer cells in bone marrow at primary surgery","subtitle":"prognostic value in comparison with nodal status","title_sort":"Micrometastatic breast cancer cells in bone marrow at primary surgery"}],"id":{"doi":["10.1093/jnci/88.22.1652"],"eki":["1882084659"]},"origin":[{"dateIssuedDisp":"20 November 1996","dateIssuedKey":"1996"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"pubHistory":["1.1940/41(1941) -"],"part":{"issue":"22","text":"88(1996), 22, Seite 1652-1658","extent":"7","volume":"88","year":"1996","pages":"1652-1658"},"origin":[{"dateIssuedDisp":"1941-","publisher":"Oxford Univ. Press","publisherPlace":"Oxford","dateIssuedKey":"1941"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"zdb":["1465951-7"],"eki":["265780713"],"issn":["1460-2105"]},"language":["eng"],"title":[{"title":"Journal of the National Cancer Institute","subtitle":"JNCI","title_sort":"Journal of the National Cancer Institute"}],"recId":"265780713","note":["Gesehen am 18.02.14"],"corporate":[{"display":"National Cancer Institute","roleDisplay":"VerfasserIn","role":"aut"}],"titleAlt":[{"title":"Journal of the National Cancer Institute online"},{"title":"JNCI"}],"disp":"National Cancer InstituteJournal of the National Cancer Institute"}]} 
SRT |a DIELINGOJKMICROMETAS2019